Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success.

Méndez-Lagares G, Lu D, Chen C, Terrault N, Segal MR, Khalili M, Monto A, Shen H, Manos MM, Lanier LL, Ryan JC, McCune JM, Hartigan-O'Connor DJ.

J Immunol. 2018 Feb 1;200(3):1124-1132. doi: 10.4049/jimmunol.1701364. Epub 2017 Dec 20.

2.

Leukoplakia, Oral Cavity Cancer Risk, and Cancer Survival in the U.S. Elderly.

Yanik EL, Katki HA, Silverberg MJ, Manos MM, Engels EA, Chaturvedi AK.

Cancer Prev Res (Phila). 2015 Sep;8(9):857-63. doi: 10.1158/1940-6207.CAPR-15-0091. Epub 2015 Jul 9.

3.

Cytology and human papillomavirus co-test results preceding incident high-grade cervical intraepithelial neoplasia.

Park IU, Wojtal N, Silverberg MJ, Bauer HM, Hurley LB, Manos MM.

PLoS One. 2015 Mar 20;10(3):e0118938. doi: 10.1371/journal.pone.0118938. eCollection 2015.

4.

Rate of congenital toxoplasmosis in large integrated health care setting, California, USA, 1998-2012.

Jones JL, Shvachko VA, Wilkins EE, Bergen R, Manos MM.

Emerg Infect Dis. 2014 Sep;20(9):1573-4. doi: 10.3201/eid2009.131919. No abstract available.

5.

Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting.

Price JC, Murphy RC, Shvachko VA, Pauly MP, Manos MM.

Dig Dis Sci. 2014 Dec;59(12):3043-52. doi: 10.1007/s10620-014-3294-0. Epub 2014 Aug 8.

6.

Mortality caused by chronic liver disease among American Indians and Alaska Natives in the United States, 1999-2009.

Suryaprasad A, Byrd KK, Redd JT, Perdue DG, Manos MM, McMahon BJ.

Am J Public Health. 2014 Jun;104 Suppl 3:S350-8. doi: 10.2105/AJPH.2013.301645. Epub 2014 Apr 22.

7.

Characteristics and management of patients with chronic hepatitis B in an integrated care setting.

Sarkar M, Shvachko VA, Ready JB, Pauly MP, Terrault NA, Peters MG, Manos MM.

Dig Dis Sci. 2014 Sep;59(9):2100-8. doi: 10.1007/s10620-014-3142-2. Epub 2014 Apr 12.

8.

Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis.

Saxena V, Manos MM, Yee HS, Catalli L, Wayne E, Murphy RC, Shvachko VA, Pauly MP, Chua J, Monto A, Terrault NA.

Aliment Pharmacol Ther. 2014 May;39(10):1213-24. doi: 10.1111/apt.12718. Epub 2014 Mar 24.

9.

Monocyte activation by interferon α is associated with failure to achieve a sustained virologic response after treatment for hepatitis C virus infection.

Hartigan-O'Connor DJ, Lin D, Ryan JC, Shvachko VA, Cozen ML, Segal MR, Terrault NA, Lanier LL, Manos MM, McCune JM.

J Infect Dis. 2014 May 15;209(10):1602-12. doi: 10.1093/infdis/jit801. Epub 2013 Dec 10.

10.

The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting.

Manos MM, Darbinian J, Rubin J, Ray GT, Shvachko V, Denis B, Velez F, Quesenberry C.

J Manag Care Pharm. 2013 Jul-Aug;19(6):438-47.

11.
12.

Distribution of hepatitis C virus genotypes in a diverse US integrated health care population.

Manos MM, Shvachko VA, Murphy RC, Arduino JM, Shire NJ.

J Med Virol. 2012 Nov;84(11):1744-50. doi: 10.1002/jmv.23399.

PMID:
22997077
13.

Reports from today's health care environment on the implementation of screening, diagnosis, and treatment recommendations.

Kim WR, Valdiserri RO, Wright LN, Manos MM, Do ST.

J Fam Pract. 2010 Apr;59(4 Suppl):S43-50. No abstract available.

PMID:
20398590
14.

Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C.

Parkes J, Guha IN, Roderick P, Harris S, Cross R, Manos MM, Irving W, Zaitoun A, Wheatley M, Ryder S, Rosenberg W.

J Viral Hepat. 2011 Jan;18(1):23-31. doi: 10.1111/j.1365-2893.2009.01263.x.

PMID:
20196799
15.

Appropriate human papillomavirus vaccination strategies.

Manos MM.

Lancet. 2009 Oct 17;374(9698):1328; author reply 1328-9. doi: 10.1016/S0140-6736(09)61821-3. No abstract available.

PMID:
19837249
16.

Complementary and alternative medicine use in chronic liver disease patients.

Ferrucci LM, Bell BP, Dhotre KB, Manos MM, Terrault NA, Zaman A, Murphy RC, Vanness GR, Thomas AR, Bialek SR, Desai MM, Sofair AN.

J Clin Gastroenterol. 2010 Feb;44(2):e40-5. doi: 10.1097/MCG.0b013e3181b766ed.

17.

The epidemiology and clinical characteristics of patients with newly diagnosed alcohol-related liver disease: results from population-based surveillance.

Sofair AN, Barry V, Manos MM, Thomas A, Zaman A, Terrault NA, Murphy RC, Stabach N, Huie S, Van Ness G, Bell BP, Bialek S.

J Clin Gastroenterol. 2010 Apr;44(4):301-7. doi: 10.1097/MCG.0b013e3181b3f760.

PMID:
19745759
18.

Prevalence and predictors of hepatic steatosis in adults with newly diagnosed chronic liver disease due to hepatitis C.

Hayman AV, Sofair AN, Manos MM, Thomas A, Terrault N, Ness GV, Stabach N, Robert M, Rumore G, Corless C, Bell B, Bialek S, Zaman A.

Medicine (Baltimore). 2009 Sep;88(5):302-6. doi: 10.1097/MD.0b013e3181b954f4.

19.

The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance.

Bell BP, Manos MM, Zaman A, Terrault N, Thomas A, Navarro VJ, Dhotre KB, Murphy RC, Van Ness GR, Stabach N, Robert ME, Bower WA, Bialek SR, Sofair AN.

Am J Gastroenterol. 2008 Nov;103(11):2727-36; quiz 2737. doi: 10.1111/j.1572-0241.2008.02071.x. Epub 2008 Jul 31.

PMID:
18684170
20.

Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study.

Avins AL, Manos MM, Ackerson L, Zhao W, Murphy R, Levin TR, Watson DJ, Hwang PM, Replogle A, Levine JG.

Drug Saf. 2008;31(4):325-34.

PMID:
18366243
21.

Limitations of conventionally derived chronic liver disease mortality rates: Results of a comprehensive assessment.

Manos MM, Leyden WA, Murphy RC, Terrault NA, Bell BP.

Hepatology. 2008 Apr;47(4):1150-7. doi: 10.1002/hep.22181.

PMID:
18264998
22.

Incidence of hepatocellular carcinoma among individuals with hepatitis B virus infection identified using an automated data algorithm.

Ulcickas Yood M, Quesenberry CP Jr, Guo D, Wells K, Shan J, Sanders L, Skovron ML, Iloeje U, Caldwell C, Manos MM.

J Viral Hepat. 2008 Jan;15(1):28-36. Epub 2007 Sep 24.

PMID:
18088242
23.

Incidence of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection.

Ulcickas Yood M, Quesenberry CP Jr, Guo D, Caldwell C, Wells K, Shan J, Sanders L, Skovron ML, Iloeje U, Manos MM.

Hepatology. 2007 Jul;46(1):107-12.

PMID:
17526021
24.

A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris.

Zane LT, Leyden WA, Marqueling AL, Manos MM.

Arch Dermatol. 2006 Aug;142(8):1016-22.

PMID:
16924051
25.

Late-stage breast cancer among women with recent negative screening mammography: do clinical encounters offer opportunity for earlier detection?

Mouchawar J, Taplin S, Ichikawa L, Barlow WE, Geiger AM, Weinmann S, Gilbert J, Manos MM, Ulcickas Yood M.

J Natl Cancer Inst Monogr. 2005;(35):39-46.

PMID:
16287884
26.

Characteristics of women refusing follow-up for tests or symptoms suggestive of breast cancer.

Weinmann S, Taplin SH, Gilbert J, Beverly RK, Geiger AM, Yood MU, Mouchawar J, Manos MM, Zapka JG, Westbrook E, Barlow WE.

J Natl Cancer Inst Monogr. 2005;(35):33-8.

PMID:
16287883
27.

Cervical cancer in women with comprehensive health care access: attributable factors in the screening process.

Leyden WA, Manos MM, Geiger AM, Weinmann S, Mouchawar J, Bischoff K, Yood MU, Gilbert J, Taplin SH.

J Natl Cancer Inst. 2005 May 4;97(9):675-83.

PMID:
15870438
28.

Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease.

Weston SR, Leyden W, Murphy R, Bass NM, Bell BP, Manos MM, Terrault NA.

Hepatology. 2005 Feb;41(2):372-9.

PMID:
15723436
29.

Reason for late-stage breast cancer: absence of screening or detection, or breakdown in follow-up?

Taplin SH, Ichikawa L, Yood MU, Manos MM, Geiger AM, Weinmann S, Gilbert J, Mouchawar J, Leyden WA, Altaras R, Beverly RK, Casso D, Westbrook EO, Bischoff K, Zapka JG, Barlow WE.

J Natl Cancer Inst. 2004 Oct 20;96(20):1518-27.

PMID:
15494602
30.

Processes of care in cervical and breast cancer screening and follow-up--the importance of communication.

Zapka JG, Puleo E, Taplin SH, Goins KV, Ulcickas Yood M, Mouchawar J, Somkin C, Manos MM.

Prev Med. 2004 Jul;39(1):81-90.

PMID:
15207989
31.

Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer.

Castle PE, Lorincz AT, Scott DR, Sherman ME, Glass AG, Rush BB, Wacholder S, Burk RD, Manos MM, Schussler JE, Macomber P, Schiffman M.

J Clin Microbiol. 2003 Sep;41(9):4022-30.

32.

A framework for improving the quality of cancer care: the case of breast and cervical cancer screening.

Zapka JG, Taplin SH, Solberg LI, Manos MM.

Cancer Epidemiol Biomarkers Prev. 2003 Jan;12(1):4-13. Review.

33.

Healthcare utilization by women in a comprehensive managed care population subsequent to diagnosis of a sexually transmitted disease.

Wilson SR, Brown NL, Leyden WA, Manos MM, Chin V, Levin D, Braverman P, Shapiro S, Lavori PW.

Sex Transm Dis. 2002 Nov;29(11):678-88.

PMID:
12438905
34.

A community-based collaboration to assess and improve medical insurance status and access to health care of Latino children.

Manos MM, Leyden WA, Resendez CI, Klein EG, Wilson TL, Bauer HM.

Public Health Rep. 2001 Nov-Dec;116(6):575-84.

35.

Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity.

Castle PE, Shields T, Kirnbauer R, Manos MM, Burk RD, Glass AG, Scott DR, Sherman ME, Schiffman M.

Sex Transm Dis. 2002 Mar;29(3):182-7.

PMID:
11875380
36.

Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom.

Scott DR, Hagmar B, Maddox P, Hjerpe A, Dillner J, Cuzick J, Sherman ME, Stoler MH, Kurman RJ, Kiviat NB, Manos MM, Schiffman M.

Cancer. 2002 Feb 25;96(1):14-20.

37.

Atypical glandular cells of undetermined significance (AGUS): Interobserver reproducibility in cervical smears and corresponding thin-layer preparations.

Lee KR, Darragh TM, Joste NE, Krane JF, Sherman ME, Hurley LB, Allred EM, Manos MM.

Am J Clin Pathol. 2002 Jan;117(1):96-102.

PMID:
11789738
38.

HPV testing for clarifying borderline cervical smear results.

Manos MM.

BMJ. 2001 Apr 14;322(7291):878-9. No abstract available.

39.

A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types.

Liaw KL, Hildesheim A, Burk RD, Gravitt P, Wacholder S, Manos MM, Scott DR, Sherman ME, Kurman RJ, Glass AG, Anderson SM, Schiffman M.

J Infect Dis. 2001 Jan 1;183(1):8-15. Epub 2000 Nov 16.

PMID:
11087198
40.

Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions.

Wideroff L, Schiffman M, Haderer P, Armstrong A, Greer CE, Manos MM, Burk RD, Scott DR, Sherman ME, Schiller JT, Hoover RN, Tarone RE, Kirnbauer R.

J Infect Dis. 1999 Nov;180(5):1424-8.

PMID:
10515799
41.

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N.

J Pathol. 1999 Sep;189(1):12-9.

PMID:
10451482
42.

Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection.

Ronnett BM, Manos MM, Ransley JE, Fetterman BJ, Kinney WK, Hurley LB, Ngai JS, Kurman RJ, Sherman ME.

Hum Pathol. 1999 Jul;30(7):816-25.

PMID:
10414501
43.

Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions.

Liaw KL, Glass AG, Manos MM, Greer CE, Scott DR, Sherman M, Burk RD, Kurman RJ, Wacholder S, Rush BB, Cadell DM, Lawler P, Tabor D, Schiffman M.

J Natl Cancer Inst. 1999 Jun 2;91(11):954-60.

PMID:
10359548
44.

Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.

Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, Ransley JE, Fetterman BJ, Hartinger JS, McIntosh KM, Pawlick GF, Hiatt RA.

JAMA. 1999 May 5;281(17):1605-10.

PMID:
10235153
45.

"ASCUS, rule out HSIL": cytologic features, histologic correlates, and human papillomavirus detection.

Sherman ME, Tabbara SO, Scott DR, Kurman RJ, Glass AG, Manos MM, Burk RD, Rush BB, Schiffman M.

Mod Pathol. 1999 Apr;12(4):335-42.

PMID:
10229496
46.

Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States.

Hildesheim A, Schiffman M, Scott DR, Marti D, Kissner T, Sherman ME, Glass AG, Manos MM, Lorincz AT, Kurman RJ, Buckland J, Rush BB, Carrington M.

Cancer Epidemiol Biomarkers Prev. 1998 Nov;7(11):1035-41.

47.

Women's health and human rights in Afghanistan.

Rasekh Z, Bauer HM, Manos MM, Iacopino V.

JAMA. 1998 Aug 5;280(5):449-55.

PMID:
9701081
48.

Where's the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses.

Kinney WK, Manos MM, Hurley LB, Ransley JE.

Obstet Gynecol. 1998 Jun;91(6):973-6.

PMID:
9611007
49.

A nested case-control study of dietary factors and the risk of incident cytological abnormalities of the cervix.

Wideroff L, Potischman N, Glass AG, Greer CE, Manos MM, Scott DR, Burk RD, Sherman ME, Wacholder S, Schiffman M.

Nutr Cancer. 1998;30(2):130-6.

PMID:
9589431
50.

Comparison of the hybrid capture tube test and PCR for detection of human papillomavirus DNA in cervical specimens.

Cope JU, Hildesheim A, Schiffman MH, Manos MM, Lörincz AT, Burk RD, Glass AG, Greer C, Buckland J, Helgesen K, Scott DR, Sherman ME, Kurman RJ, Liaw KL.

J Clin Microbiol. 1997 Sep;35(9):2262-5.

Supplemental Content

Loading ...
Support Center